Morat Nicola, Civieri Giovanni, Spezia Matteo, Menegolo Mirko, Bernava Giacomo, Iliceto Sabino, Iop Laura, Tona Francesco
Cardiology Division, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy.
Vascular Surgery Division, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy.
Int J Mol Sci. 2025 Aug 4;26(15):7527. doi: 10.3390/ijms26157527.
The pivotal role of angiotensin II (AngII) in cardiovascular disease has been firmly established, as evidenced by a robust body of literature and the broad clinical application of AngII-inhibiting therapies. AngII type 1 receptor is the primary mediator of AngII action, and its activation initiates a multitude of cellular responses that contribute to the development of hypertension, structural changes in the heart and vasculature, and damage to target organs. This review examines AngII from a different perspective, exploring the link between the renin-angiotensin-aldosterone system and cardiovascular risk beyond hypertension, with particular emphasis on atherosclerosis development and progression.
血管紧张素II（AngII）在心血管疾病中的关键作用已得到确凿证实，大量文献以及AngII抑制疗法的广泛临床应用都证明了这一点。血管紧张素II 1型受体是AngII作用的主要介质，其激活引发多种细胞反应，这些反应导致高血压的发展、心脏和血管系统的结构变化以及靶器官的损伤。本综述从不同角度审视AngII，探讨肾素-血管紧张素-醛固酮系统与高血压以外的心血管风险之间的联系，特别强调动脉粥样硬化的发生和发展。
